This revised Program Project grant proposal entitled. Mechanisms of Esophageal Carcinogenesis. seeks to define and elucidate the molecular mechanisms underlying squamous cell carcinogenesis in the esophagus with eventual translation to new strategies in diagnosis and therapy. Based upon historical interactive collaborations between the Project Leaders and usage of the Scientific Core Facilities, this program project focuses upon hypothesis-driven research that is innovative. The experience and expertise of the Project Leaders, in concert with the platforms provided by the Core Facilities, will result in enhancement of the research that would not be possible if the projects were independent of each other. Project 1 (Rustgi, Project Leader) will focus upon the biological roles of epidermal growth factor receptor (EGFR) overexpression in the early or precursor stages of esophageal carcinogenesis and their functional consequences. Project 2 (Herlyn, Project Leader) will emphasize the interplay of epithelial-stromal interactions, especially the EGF and TGFbeta receptor systems, and their influence on esophageal carcinogenesis. Project 3 (El-Deiry, Project Leader) will elucidate the role of the TRAIL apoptotic pathway in esophageal carcinogenesis. Importantly, the projects are further united by their utilization of unique organotypic cultures and genetically engineered mice that have esophageal epithelial specific gene expression, both developed by the Project Leaders. Three highly successful Core facilities are designed to provide esophageal cancer-specific services for the stimulation of collaborative research: Morphology, Molecular Biology/Gene Expression and Administrative. This Program Project has the unequivocal support of the University of Pennsylvania Cancer Center and Medical School and as such will foster interdisciplinary research that leads to a cooperative understanding of the molecular processes that form and regulate esophageal carcinogenesis. Finally, the Program Project is in concert with the NCI Progress Review Group for esophageal and stomach cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098101-04
Application #
7093570
Study Section
Subcommittee G - Education (NCI)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2003-08-15
Project End
2008-06-30
Budget Start
2006-08-07
Budget End
2007-06-30
Support Year
4
Fiscal Year
2006
Total Cost
$1,497,773
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Campbell, Joshua D; Yau, Christina; Bowlby, Reanne et al. (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23:194-212.e6
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478
Giroux, VĂ©ronique; Stephan, Julien; Chatterji, Priya et al. (2018) Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating. Stem Cell Reports 10:1947-1958
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Bockorny, Bruno; Rusan, Maria; Chen, Wankun et al. (2018) RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther 17:1526-1539
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Karakasheva, Tatiana A; Dominguez, George A; Hashimoto, Ayumi et al. (2018) CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3:

Showing the most recent 10 out of 173 publications